At what enterprise value was D.O.R.C. (DUTCH OPHTHALMIC RESEARCH CENTER) acquired in 2019?

During the acquisition of D.O.R.C. (DUTCH OPHTHALMIC RESEARCH CENTER) by EURAZEO in 2019, the transaction's Enterprise Value is estimated to be in the range of 300M - 700M EUR.

What was the revenue of D.O.R.C. (DUTCH OPHTHALMIC RESEARCH CENTER) at the time of the deal?

The revenue of D.O.R.C. (DUTCH OPHTHALMIC RESEARCH CENTER) at the time of the deal is estimated to be in the range of 100M - 200M EUR.

How is the data for the D.O.R.C. (DUTCH OPHTHALMIC RESEARCH CENTER) acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the D.O.R.C. (DUTCH OPHTHALMIC RESEARCH CENTER) deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://fr.newsroom.eurazeo.com/assets/2019-04-25-dorc-fr-v06-pdf-f4870-7ed35.html

What is the average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026?

The average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026 is 14.3x.

← DATABASE

Home Database Healthcare & PharmaD.O.R.C. (DUTCH OPHTHALMIC RESEARCH CENTER)

04/2019

D.O.R.C. (DUTCH OPHTHALMIC RESEARCH CENTER) acquired by EURAZEO

NETHERLANDS Life Sciences / Medical Devices EV 300M - 700M EUR

Context

Eurazeo Capital completed the acquisition of 100% of the share capital of D.O.R.C. from its previous owners. The transaction positions Eurazeo as the majority shareholder of a rapidly growing MedTech player in the dynamic ophthalmic surgery market. The strategic plan focuses on capitalizing on D.O.R.C.'s highly regarded brand and innovative technology to drive further international growth, with a specific priority on capturing market share in the US. Eurazeo also intends to support the company's shift towards a higher mix of recurring revenue through its proprietary consumables and surgical packs.

D.O.R.C. (DUTCH OPHTHALMIC RESEARCH CENTER), which reported an EBITDA margin of in 2018, is valued in this transaction at an EV/EBITDA multiple of , a level to compare with the average currently observed in the Healthcare & Pharma sector (14.3x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Headquartered in the Netherlands, D.O.R.C. is a global leader in ophthalmic surgery equipment. It specializes in the "posterior segment" of the eye (vitreoretinal surgery). Its flagship product, the EVA Nexus platform, is a dual-function system used for both cataract and retina surgeries, highly regarded by surgeons for its precision.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2018

2017

Other operations with D.O.R.C. (DUTCH OPHTHALMIC RESEARCH CENTER)

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
08/2023	CARL ZEISS MEDITEC	D.O.R.C. (DUTCH OPHTHALMIC RESEARCH CENTER)	NETHERLANDS	Medical Devices

REFERENCES

Valuation range: EV 300M - 700M EUR

Revenue range: 100M - 200M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of D.O.R.C. (DUTCH OPHTHALMIC RESEARCH CENTER) by EURAZEO are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Press release: view release

Acquirer: eurazeo